| Page 14 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Treatment of lower-risk myelodysplastic syndromes

Author(s): 
Merz AMA, Platzbecker U
Primary Author: 
Merz AMA
Journal Title: 
Haematologica
Original Publication Date: 
Oct 2024

Myelodysplastic neoplasms (MDS) involve clonal hematopoiesis and cellular dysplasia, driven by genetic and epigenetic alterations. Spliceosome mutations and epigenetic dysregulation underscore the intricate pathogenesis of MDS. The

Bone Marrow Disease(s): 

Future directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology

Author(s): 
Della Porta MG, Bewersdorf JP, Wang YH, Hasserjian RP
Primary Author: 
Della Porta MG
Journal Title: 
Histopathology
Original Publication Date: 
Oct 2024

Bone Marrow Disease(s): 

Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions

Author(s): 
Bidikian A, Bewersdorf JP, Shallis RM, Getz TM, Stempel JM, Kewan T, Stahl M, Zeidan AM
Primary Author: 
Bidikian A
Journal Title: 
Expert Review of Anticancer Therapy
Original Publication Date: 
Oct 2024

Introduction: 

Bone Marrow Disease(s): 

Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature

Author(s): 
Nasnas P, Ling J, Gerstein Y, Wang SA, Loghavi S, Hammond D, Montalban-Bravo G, Senapati J, Pemmaraju N, Corredor J, Pierce S, Roth M, Ravandi F, Cuglievan B, Kadia T, DiNardo CD
Primary Author: 
Nasnas P
Journal Title: 
Clinical Lymphoma, Myeloma & Leukemia
Original Publication Date: 
Oct 2024

Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial

Summary
Background
Access to allogeneic haematopoietic stem-cell transplantation (HSCT) remains challenging for older patients (aged >60 years) with acute myeloid leukaemia. We aimed to evaluate the efficacy of venetoclax plus decitabine as first-line therapy and bridge to transplantation in this patient population.
Methods

Exercise Treatment as Part of Multidisciplinary Whole Person Care in Oncology

Several national agencies, including the American Society of Clinical Oncology (ASCO), recommend the prescription of exercise for patients diagnosed with cancer.1,2 The evidence base for this recommendation is derived from studies that showed exercise-related improvements in patient-reported outcomes (PROs), treatment-associated adverse effects, cardiorespiratory fitness (CRF), and overall physical functioning.3-6 Additionally, exercise may have direct anticancer effects and indirect effects by synergizing standard cancer therapies.7,8 Despite these benefits, the implementation of exercise